IRWD Positive Sentiment
Ironwood to Present New Data at NASPGHAN Annual Meeting Reinforcing Impact of Linaclotide on Functional Constipation in Children and Adolescents Ages 6-17 Years-Old
Key Takeaway: Ironwood Pharmaceuticals announced that it will present new data at the NASPGHAN Annual Meeting. The data highlights the impact of Linaclotide on treating functional constipation in children and adolescents aged 6 to 17 years. This presentation aims to reinforce the drug's effectiveness in this demographic.
Price reaction · baseline $9.65 (2023-10-04 close) · hit after-hours · clean, no other IRWD news in the window
day 0 close · peak
+0.9%
Market Sentiment Analysis
POSITIVE FACTORS
- New data presented reinforces the effectiveness of Linaclotide.
- Focus on treating functional constipation in children and adolescents.
- Presentation at a reputable annual meeting enhances credibility.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+57%
120-day peak, hindsight
Typical move
3.8%
average across 2 past catalysts
Lead asset
IW-3718
Phase 3 · Gastroesophageal Reflux Disease (GERD)
Frequently Asked Questions
What is the focus of Ironwood's presentation?
Ironwood's presentation focuses on the impact of Linaclotide on functional constipation in children and adolescents.
What age group is being studied for Linaclotide?
The study involves children and adolescents aged 6 to 17 years.
Where will the new data be presented?
The new data will be presented at the NASPGHAN Annual Meeting.
What is Linaclotide used for?
Linaclotide is used to treat functional constipation.